Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
about
Axitinib in Metastatic Renal Cell CarcinomaTumor stroma as targets for cancer therapyMolecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitorsValidation of housekeeping gene and impact on normalized gene expression in clear cell renal cell carcinoma: critical reassessment of YBX3/ZONAB/CSDA expressionHigh dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.TM4SF1 Promotes Proliferation, Invasion, and Metastasis in Human Liver Cancer CellsTumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinomaVascular endothelial growth factor gene polymorphisms and the risk of renal cell carcinoma: Evidence from eight case-control studies.The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities.New agents in renal cell carcinoma.Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.Axitinib for the treatment of metastatic renal cell carcinoma.Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS).Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with pazopanib.Conditional survival in patients treated with vascular endothelial growth factor-targeted therapy for advanced renal cell carcinoma.Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab
P2860
Q26998017-92CDB0C1-3486-4236-ABE4-40796AC85F0FQ27015980-9A9FC60B-1B2C-4699-9A60-F47382EBB944Q27673353-B8A62775-6392-4E5F-A092-935F6C329B3FQ33712289-85629E03-AA1F-4356-9BD5-8806DACE21E0Q35672426-498BA467-AE18-4747-BCE0-10E3EF5BA4FBQ36192083-AB281076-086A-48E4-A73B-F6CFB724BA43Q36378883-3ED1594C-A6EC-4F1F-A482-425A3F32EBF7Q36939173-A77F3738-CBCC-4D2A-BD61-42A673EAA5D9Q37681761-520434A7-F5A4-4E52-A2D9-77348EE67148Q37702734-7ACE3F74-E343-4F54-8770-B7B2F14EA130Q37987661-50611841-A6E2-44F0-9AA3-84E8A34E6C22Q38163483-EF9C8569-6161-41E0-87FB-84BAACF235DFQ38171376-519EF519-5C6F-45C0-98F0-1AD270316620Q38697227-5675CCD0-ADEE-494E-AF4C-5DF8A7BBCE4BQ38815893-A7871620-D873-4B7C-A2E3-A29018C43F26Q42236729-1222C5FB-F72C-4E6D-8549-B45A7BF918A3Q42413228-A20A858A-AAED-4613-8152-23CBD6EEC116Q44913756-5A50240B-4494-432F-984D-EDD838F8357BQ58545576-6615B1D4-C66B-49EA-A8A8-11082F4C258D
P2860
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
@en
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
@nl
type
label
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
@en
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
@nl
prefLabel
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
@en
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
@nl
P2093
P1476
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
@en
P2093
Brian Rini
Laurence Albiges
Mohamed Salem
P304
P356
10.1016/J.HOC.2011.04.006
P577
2011-08-01T00:00:00Z